HyClone CDM4MAb Media is a regulatory-friendly media devleoped through Metabolic Pathway Design approach to increase process yields for the manufacture of antibodies for therapeutic use in a variety of engineered hybridoma and recombinant myeloma cell lines.
CDM4MAb contains Pluronic F68 and does not contain Phenol Red. It is available with and without L-glutamine.
Highlights:
Regulatory-friendly medium developed through Metabolic Pathway Design for therapeutic use in a variety of engineered hybridoma and myeloma cell lines
Successfully tested in a variety of culture systems, including T-flasks, shaker flasks and bioreactors, including fed-batch and perfusion